A patient had clinical and radiographic findings suggestive of allergic bronchopulmonary aspergillosis. Further studies excluded this diagnosis but indicated that the patient’s respiratory disease was due to the yeast Torulopsis glabrata, usually nonpathogenic in normal human hosts. The patient had no evidence of invasive disease. Total serum IgE was elevated but IgE antibody against T. glabrata could not be demonstrated by skin test or radioimmunoassay. Demonstration of elevated IgG antibody against T. glabrata antigen by radioimmunoassay was of value in suggesting the diagnosis. The patient responded to prednisone therapy with clinical and radiographic improvement and with a sharp decline in total serum IgE, and a lesser degree of decline in total serum IgG and IgA. Bronchopulmonary torulopsosis may be rare but should be considered in cases where the diagnosis of allergic bronchopulmonary aspergillosis cannot be established. Because IgE antibody could not be incriminated in this disease the term allergic bronchopulmonary torulopsosis was not used in this case.

This content is only available via PDF.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.